Home/Pipeline/AL5882

AL5882

Solid Tumors

Phase I/IIActive

Key Facts

Indication

Solid Tumors

Phase

Phase I/II

Status

Active

Company

Shanghai Allist Pharmaceuticals

About Shanghai Allist Pharmaceuticals

Shanghai Allist Pharmaceuticals, founded in 2004, is a publicly traded biopharmaceutical innovator with a mission to leverage technology for improving patient lives. The company has successfully transitioned from a research organization to an integrated enterprise with a focus on kinase inhibitors for oncology and drugs for metabolic diseases, culminating in a high-profile IPO on the Shanghai STAR Market. Its strategy centers on advancing a deep clinical pipeline, capitalizing on China's supportive innovation policies, and pursuing global partnerships to maximize the value of its novel therapeutics.

View full company profile

Therapeutic Areas

Oncology Metabolic Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed
Undisclosed Whole Cell Vaccine Program(s)	Neuvogen	Pre-clinical	Active
SY-5609	Syros Pharmaceuticals	Phase 1/2	Discontinued
Not Specified (TCR Therapy)	T-Cure Bioscience	Phase 1	Active
B7-H3 Program	Ocean Biomedical	Discovery	Active